<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To reduce the risk of graft rejection after allogeneic hematopoietic cell transplantation (alloHCT) for patients with acquired severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA), we introduced an intensified preparative regimen consisting of treosulfan 10 g/m2/d on days -7, -6, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 40 mg/kg/d on days -5, -4, -3, -2 and anti-thymocyte globulin 2 mg/kg/d on days -3, -2, -1 </plain></SENT>
<SENT sid="1" pm="."><plain>Six patients with the history of multiple transfusions were treated with alloHCT from either HLA-identical sibling (n=3) or an unrelated volunteer (n=3) </plain></SENT>
<SENT sid="2" pm="."><plain>Each, bone marrow and peripheral blood was used as a source of stem cells in three cases </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients engrafted and achieved complete donor chimerism </plain></SENT>
<SENT sid="4" pm="."><plain>None of the patients experienced severe organ toxicity </plain></SENT>
<SENT sid="5" pm="."><plain>No severe <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host-disease</z:e> (GVHD) was observed; two patients experienced extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="6" pm="."><plain>At the median follow-up of 14.5 (13-27) months <z:hpo ids='HP_0000001'>all</z:hpo> patients remained alive and disease-free </plain></SENT>
<SENT sid="7" pm="."><plain>Our observation indicates that treosulfan + <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> + antithymocyte globulin conditioning is well-tolerated and allows stable engraftment in acquired SAA </plain></SENT>
</text></document>